Kaneka Logo
Health Care Professionals PhotoFor Health Care Professionals

References

Some of the references may include discussions of off-label uses not listed in the approved Full Prescribing Information included in this site. Kaneka Pharma America LLC has included these abstracts as educational and background information only.

1.

Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T, and the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82:1489-1495.

2.

M.Matsuzaki, K.Hiramori, T.Imaizumi, A. Kitabatake, H. Hishida, M. Nomura, T. Fujii, I. Sakuma, K. Fukami, T. Honda, H. Ogawa, M. Yamagishi. Intravascular Ultrasound Evaluation of Coronary Plaque Regression by Low Density Lipoprotein-Apheresis in Familial Hypercholesterolemia J Am Coll Cardiol 2002;40:220-227.

3.

Tamai 0, Matsuoka H, ltabe H, Wada Y, Kohno K, lmaizumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997; 95:76-82.

4. Tamai O., Matsuoka H., and Imaizumi T.:Improvement of Endothelium-Dependent Vasodilatation in Hypercholesterolemic Humans by Single LDL Apheresis Japanese Journal of Apheresis. 1996;15:268-274.
5. Otto C., Geiss H., Empen K., and Parhofer K.: Long-term reduction of C-reactive protein concentration by regular LDL Apheresis. Atherosclerosis 174 (2004) 151-156.
6. Kobayashi J., Katsube S., Shimoda M., Furuhashi K., Kitano S., Masuda M., Maruyama T., and Shinomiya M.: Single LDL Apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clinica Chimica Acta 321 (2002) 107-112.
7. Stefanutti C., Lanti A., Di Giacomo S., Mareri M., De Lorenzo F., Landolfo A., and Isacchi G.: Therapeutic apheresis in low weight patients: technical feasibility, tolerance, compliance, and risks. Transfusion and Apheresis Science 31(2004) 3-10.
8. Igarashi K., Tsuji M., Nishimura M., and Horimoto M.: Improvement of Endothelium-Dependent Coronary Vasodilation After a Single LDL Apheresis in Patients with Hypercholesteloremia. Journal of Clinical Apheresis 2004;19:11-16.
9. Kanemitsu S., Takekoshi N., Matsui S., Tsugawa H., Ohkubo S., Kitayama M., Matsuda T., Senma J., Masuyama K., Yamagata T., and Murakami E.: Short-Term and Long-Term Effects of Low-Density Lipoprotein (LDL) Apheresis on Restenosis after Percutaneous Transluminal Coronary Angioplasty (PTCA): Is Lowering Lp(a) by LDL Apheresis Effective on Restenosis after PTCA? Therapeutic Apheresis 2(1): 65-70.
10. Kanemitsu S., Takekoshi N., and Murakami E.: Effects of LDL apheresis on restenosis after angioplasty.
11. Berliner S., Ben-Ami R., Samocha-Bonet D., Abu-Abeid S., Schechner V., Beigel Y., Shapira I., Yedgar S., and Barshtein G.: The Degree of red blood cell aggregation on peripheral blood glass slides corresponds to inter-erythrocyte cohesive forces in laminar flow. Thrombosis Research (2004) 114, 37-44.
12.

Stefanutti C, Di Giacomo S, Vivenzio A, Isacchi G.C, Masella R, Caprari P, et al. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia. Clinical Science 2001; 100:191-198.

13.

Stefanutti C, Di Giacomo S, Vivenzio A, Colloridi V, Bosco G, Berni A, et al. Low-density lipoprotein apheresis in a patient aged 3.5 years. ACTA PAEDIATR 2001; 90:694-701.

14.

Takahashi K, Kobayashi J, Bujo H, Takahashi M, Taira K, et al. Long-term (14 years) Effect of LDL Apheresis on Obstructive Changes in Aortocoronary Saphenous-vein Bypass Grafts in a Case of Heterozygous Familial Hypercholesterolemia with the LDL Receptor Proline664 to Leucine Mutation. Intern Med 2000; 39(10):804-809.

15.

Lepage S, Nigon F, Bonnefont-Rousselot D, Assogba U, Goulinet S, Chancharme L, et al. Oxidizability of Atherogenic Low-Density Lipoprotein Subspecies in Severe Familial Hypercholesterolemia: Impact of Long-Term Low-Density Lipoprotein Apheresis. J Cardiovasc Pharmacol Therapeut 2000; 5(2):87-103.

16.

Nishimura S, Sekiguchi M, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low Density Lipoprotein-Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999; 144: 409-417.

17.

Mabuchi H, Koizumi J,Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T, and the Hokuriku-FH-LDL-Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998; 82:1489-1495.

18.

Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth R, et al. Long-term effects of low-density lipoprotain apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998; 81:407-411.

19.

Saku K, Takeda Y, Jimi S, Okabe M, Shirai K, Nii T, et al. Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholosterolemia: follow-up study using coronary angiography. J Cardiol 1998; 31:239-245.

20.
Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997; 96:1381-1385.
21.
Koga N. The retardation of progressin, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. Therap Apher 1997; 1:260-270.
22.
Kroon AA, van der Asten WNJC, Stalenhoef AFH. Effect of apheresis on low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996; 125:945-954.
23.
Kroon AA, Aengavaeren WRM, van der Werf T, Uijen GNH, Reiber JHC, Bruschke AVG, Atalenhoef AFH. LDL-Apheresis Atherosclerosis Regression Study (LAARS): effect of agressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93:1826-1835.
24.

Aengevaeren WR, Kroon AA, Stalenhoef AF, Uijen GJ, van der Werf T. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28:1696-1704.

25.
Gordon BR, Saal SD. Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 1996; 7:381-384.
26.
Thompson GR, Maher VMG, Mathews S, Kitano Y, Nenwirth C, Shortt MB, et al. Familial Hypercholesterolemia Regression Study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995; 345:811-816.
27.
Uno H, Ueki Y, Murashima J, Miyake S, Tominaga Y, Eguchi K, Yano K. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterance. Atherosclerosis 1995; 116:93-102.
28.
Gordon BR, Saal SD. Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol 1994; 5:69-73.
29.
Koizumi J, Koizumi I, Uno Y, lnazu A, Kajinami K, Haraki T, et al. Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993; 100:65- 74.

 

© Copyright Kaneka Pharma America, LLC . All rights reserved.

The information on this site is intended for U.S. residents only.